Compare COCO & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCO | LQDA |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.1B |
| IPO Year | 2021 | 2020 |
| Metric | COCO | LQDA |
|---|---|---|
| Price | $47.25 | $37.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $57.75 | $41.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.60 | ★ 51.81 |
| EPS | ★ 1.19 | N/A |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $16.12 | $278.87 |
| Revenue Next Year | $11.40 | $57.13 |
| P/E Ratio | $40.54 | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $29.74 | $11.85 |
| 52 Week High | $61.39 | $46.67 |
| Indicator | COCO | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 49.78 |
| Support Level | $45.02 | $31.75 |
| Resistance Level | $48.67 | $39.19 |
| Average True Range (ATR) | 2.54 | 2.12 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 34.18 | 37.52 |
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.